Aeglea raises $50M in IPO after slashing share price

IPOs 2016

Austin, TX-based Aeglea BioTherapeutics raised $50 million in its IPO after pricing 5 million shares at $10 each, far below the range that it had set out for itself. The enzyme-replacement biotech had hoped to sell 3.5 million shares at $16 to $18, which proved an impossible task in this turbulent market. Shares will trade under the $AGLE symbol. The biotech raised $44 million in a venture round a year ago, much of which was earmarked for a Phase I/II proof-of-concept study of AEB1102. Release

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.